久久国产中文娱乐网_日韓一級高清_a级毛片黄免费观看m_宝贝对着摄像头自己做忘羡_亚洲黄色天堂网_高清有码巨乳日本在线_俄罗斯6一12呦女精品不卡_欧美日批在线观看视频_最近中文字幕更新免費_粉嫩虎白女P虎白女在线

On May 29, the China Human Capital Forum 2018 was held in China World Hotel Beijing, announcing that the human resource team of Eisai China won the “Best HR Teams in Greater China” of?HRoot Awards?2018 for their outstanding achievements and contributions in pushing the development and innovation of the corporate, building excellent workplaces and promoting business development. Mr. Yamada Koki, Head of Pharmaceutical Affairs Division of Eisai China, Mr. Yu Ruilong, Director of Drug Affairs & Relationship Department of Eisai China, and Ms. Wang Li, Manager of Human Resource Department of Eisai China attended the award ceremony.?

Eisai Co., Ltd. (CEO: Haruo Naito; Headquarters: Tokyo, Japan) (hereinafter “Eisai”), Eisai‘s subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. (President & CEO: Yuji Matsue; Headquarters: Tokyo, Japan) (hereinafter “EA Pharma”) and Mochida Pharmaceutical Co., Ltd. (President: Naoyuki Mochida; Headquarters: Tokyo, Japan) (hereinafter “Mochida”) today announced that the bile acid transporter inhibitor “GOOFICE??5mg Tablet” (nonproprietary name: elobixibat hydrate; development code: AJG533) (hereinafter “GOOFICE??Tablet”) was listed in Japan’s National Health Insurance Drug Price List as of April 18, 2018, and EA Pharma and Mochida launched the product onto Japan‘s market today.

TOKYO March 23, 2018 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA??(generic name: lenvatinib mesylate) has been approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide for LENVIMA for the indication of unresectable HCC and the first new systemic therapy to be approved in Japan for the front-line treatment of HCC in approximately 10 years. Additionally, this is the first regulatory approval for LENVIMA under the global strategic collaboration agreement executed in March 2018 between Eisai and Merck & Co., Inc., Kenilworth N.J., U.S.A. for the co-development and co-commercialization of LENVIMA.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has completed construction of a new oral solid dose (OSD) production facility and an administration building at the site of its new Suzhou plant located within the Suzhou Industrial Park.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Aricept? (donepezil hydrochloride, brand name in China:?) has been approved for the additional indication of severe Alzheimer‘s disease in China. Aricept is the first Alzheimer’s disease treatment with a broad indication that covers mild to severe Alzheimer‘s disease in China.